Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999;19(4):291-4.
doi: 10.1007/BF02886966.

Effect of terazosin on blood pressure and serum lipids

Affiliations
Clinical Trial

Effect of terazosin on blood pressure and serum lipids

P Gong et al. J Tongji Med Univ. 1999.

Abstract

In an open multicenter prospective study, the effects of short-term (4 weeks, n = 101) and long-term (6 months, n = 38) terazosin treatment on blood pressure, serum lipids and safety in the patients with mild to moderate essential hypertension were observed. Mean systolic and diastolic blood pressure in sitting position were significantly reduced by 16.4% and 14.0% respectively (P < 0.01) after 4 weeks of terazosin therapy, with the total efficacy rate being 87.1%. During a 6 month therapy, antihypertensive effect of terazosin could be maintained. Total cholesterol (TC) and low density lipoprotein (LDL) cholesterol in serum were significantly decreased P < 0.05-0.01) in patients with hypercholesterolemia (TC > or = 6 mmol/ml) after 4 week terazosin treatment; the levels of TC, LDL and triglyceride were significantly improved in hypertensive patients after 3-6 month terazosin treatment. The improvement of lipid metabolism was related to the dosage of terazosin but not to antihypertensive effects of terazosin. The results suggested that terazosin is effective in decreasing blood pressure and improving lipid metabolism. It may serve as a good antihypertensive agent for hypertensive patients with hypercholesterolemia.

PubMed Disclaimer

Similar articles

References

    1. J Cardiovasc Pharmacol. 1989;13 Suppl 2:S1-4; discussion S4 - PubMed
    1. J Cardiovasc Pharmacol. 1989;13 Suppl 2:S5-9; discussion S9-10 - PubMed
    1. Am J Med. 1986 May 23;80(5B):82-5 - PubMed
    1. Drugs. 1986;31 Suppl 1:1-11 - PubMed

LinkOut - more resources